Duchenne muscular dystrophy (DMD) is a genetic, X-linked recessive disease with an associated cardiomyopathy characterized by myocardial fibrosis leading to heart failure, arrhythmias, and death. Earlier detection and treatment of cardiac involvement in DMD hold potential to improve outcomes. Cardiovascular magnetic resonance (CMR) extracellular volume (ECV) quantification using T1 mapping is a histologically validated, non-invasive marker of diffuse fibrosis. This study aims to determine the ECV in a pediatric DMD population, and correlate it with metrics of left ventricular function. A retrospective review of pediatric DMD subjects who underwent CMR at a single institution. A total of 47 DMD patients (mean age 14 ± 2 years) were included for analysis. Global myocardial ECV was significantly higher in the DMD group (29 ± 6%) compared with published normal values (24 ± 2%, p = 0.0001). Higher ECV values correlate with indices of left ventricular function, including decreased left ventricular ejection fraction (r = -0.46, p = 0.001) and indexed left ventricular end diastolic volume (r = 0.41, p = 0.004). ECV was not significantly higher in DMD patients with late gadolinium enhancement (LGE) (30 ± 7%) compared to DMD patients without LGE (27 ± 5%, p = 0.0717). CMR T1 mapping is a feasible method for quantification of ECV in patients with DMD. Global myocardial ECV is significantly higher in the DMD population compared to healthy controls and correlates with other metrics of myocardial function. Global myocardial ECV may serve as an important tool to determine cardiac involvement in DMD population and help guide medical management.
Introduction
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations in dystrophin gene [1] . It is the most common inherited muscular dystrophy affecting approximately 1-3500 males [2] . The clinical course is characterized by progressive skeletal muscle weakness and loss of ambulation [3, 4] . Improved therapies for associated comorbidities, namely respiratory support, have left cardiac dysfunction as the leading cause of morbidity and mortality in DMD patients [5] [6] [7] [8] [9] . Cardiac involvement in DMD follows a predictable course of progressive left ventricular systolic dysfunction [10] , with myocardial fibrosis present at autopsy [11, 12] .
The use of cardiac magnetic resonance (CMR) for diagnosis and monitoring of cardiac involvement in DMD has increased [13] , and annual CMR studies for DMD patients are routine at some institutions. CMR is an optimal tool in DMD patients for assessment of chamber size and function, and for myocardial tissue characterization. CMR late gadolinium enhancement (LGE) is an established tool for identifying focal areas of myocardial fibrosis [14] and LGE is prevalent in the DMD population [15] . It has previously been shown that the burden of LGE correlates with decline in left ventricular ejection fraction (LVEF) in DMD patients [16] . Despite these results, quantitative LGE evaluation in DMD is technically challenging [15] . LGE imaging reliance on relative signal intensity differences between diseased and normal myocardial tissue makes it more challenging to accurately detect the extent of disease involvement in diffuse myocardial disease processes [17, 18] . CMR T1 mapping techniques can determine myocardial extracellular volume (ECV) and serve as a histologically validated surrogate for diffuse myocardial fibrosis [18, 19] .
ECV is a newer CMR technique using T1-mapping used for tissue characterization. Essentially, the technique allows one to dichotomize the myocardium into its cellular and interstitial components [20] . Fibrosis leads to the accumulation of extracellular matrix proteins that increase the fraction of the myocardium that is extracellular. The administration of gadolinium-based contrast agents distributes into the plasma and myocardium. Compared to normal myocardium, post-contrast T1 values in fibrotic myocardium are shorter due to higher amount of gadolinium retained in the increased extracellular space. The ratio between pre-and post-contrast administration T1 maps is calculated and then ''normalized'' to the concentration of gadolinium in the blood and adjusted for hematocrit. This calculation provides an estimate of myocardial extracellular volume expressed as a percentage of the total myocardium. Expanded extracellular volume reflects interstitial disease.
We hypothesized that non-invasive detection of global myocardial disease burden with ECV will correlate with metrics of LV function, such as LV ejection fraction, and therefore could help direct and monitor ongoing therapy in DMD population. Previous studies have demonstrated abnormally shortened post-contrast T1 values in pediatric DMD patients [21] . The primary aim of this study was to determine the ECV in a pediatric cohort of DMD patients and compare with controls. The secondary aim was to correlate ECV with other quantifiable metrics of left ventricular function.
Methods

Study Population
A retrospective database search identified 47 patients with known duchenne muscular dystrophy (DMD) who underwent cardiac magnetic resonance (CMR) with appropriate imaging sequences. CMR examinations were performed at a single institution between March 2014 and February 2015. DMD diagnosis was confirmed by clinical examination and data, skeletal muscle pathology and/or genetic testing in all patients. The control population for comparison was derived from previously published pediatric data [22] . Demographic data and medication use at the time of CMR were collected by chart abstraction. Hematocrit data were obtained within 6 months from the time of CMR. The study was approved by the Institutional Review Board at Cincinnati Children's Hospital.
Cardiac Magnetic Resonance Imaging Protocols
CMR was performed on all patients using a 1.5 T Philips scanner (Ingenia; Philips Healthcare, Best, Netherlands). Volumetric and functional measurements were made using a standard cine SSFP short-axis stacks from the mitral annulus to the apex (2-chamber, 3-chamber, 4-chamber acquisitions were used for reference). For the SSFP images slice thickness 6 mm, pixel resolution 1.5 9 1.5 mm, phases per R-R interval adjusted to keep temporal resolution \30 ms. T1 measurements were performed using a modified Look-Locker pulse sequence before and after bolus contrast administration as previously described [23] . Modified Look-Locker sequences were performed at three short-axis slices (basal, midventricular, and apical) prior to contrast administration and 12 min after contrast. Gadoterate meglumine (Dotarem, Guerbet, Villepinte, France) 0.2 mmol/kg was used for contrast bolus. LGE images were acquired using a standard inversion recovery gradient echo pulse sequence in the same geometries as the SSFP acquisitions. The inversion recovery time was chosen to best null the myocardium.
Myocardial ECV analysis and calculations were performed with QMASS MR (Medis Medical Imaging Systems, Leiden, the Netherlands). Analysis was performed by one reader (JJS). After motion correction, epicardial and endocardial borders were manually drawn with care taken to exclude the blood pool on three different myocardial planes (basal, midventricular, and apical). Four regions of interest were drawn in each myocardial plane: septal, anterolateral, inferolateral, inferior regions. Corresponding AHA 17-segment model for basal slice, (septal: segments 2 and 3, anterolateral: segments 1 and 6, inferolateral: segments 6 and 5, inferior: segment 4) midventricular slice, (septal: segments 8 and 9, anterolateral: segments 7 and 12, inferolateral: segments 12 and 11, inferior: segment 10) apical slice, (septal: segment 14, anterolateral: segment 13, inferolateral: segment 16, inferior: segment 15) [24] . An additional region of interest for the blood pool was placed in the left ventricular cavity, avoiding myocardium, on a midventricular image. Myocardial ECV was computed with the following formula: ECV = k 9 (1 -hematocrit). Where k is the partition of coefficient defined as k = DR1 (myocardium)/DR1 (blood) [18, 23] .
Published control subjects CMR examination was performed on 1.5 T scanner (Philips Acheiva, Philips Healthcare, Best, the Netherlands). ECV image acquisition and analysis performed as described [22] .
Statistical Analysis
Statistical analysis was performed using JMP Ò , Version 6.1 (SAS Institute Inc., Cary, North Carolina, USA). Continuous variables were expressed as mean ± SD or median and interquartile range as appropriate. Categorical variables were expressed as frequency and percentages. Two tailed t test was performed for comparison of characteristics between DMD patients and controls. Linear regression analysis was performed using Pearson's correlation coefficient (r) for normally distributed data. Kruskal-Wallis H test was performed for comparison of different medication groups. Inter-and intra-observer variability are expressed as the mean difference ± SD. Table 1 describes subject characteristics at the time of the CMR study. A total of 47 patients were included in the analysis. All subjects were male. The mean age was 14 ± 4 years (range 8-24 years). Twenty-eight (60%) of the subjects were non-ambulatory. Thirty-five (74%) of subjects were taking at least one cardiovascular medication. The most common medication used was an angiotensin receptor blocker in 39 (83%) subjects. Other cardiovascular medications used included beta blockers in 32 (68%) of subjects, angiotensin-converting-enzyme inhibitors in 16 (34%) of subjects, and spironolactone in 34 (72%) of subjects. Forty-four (94%) subjects were treated with steroids. The mean LV ejection fraction was 54.8 ± 8.8%. Nineteen (40%) of the 47 subjects had an abnormally low LV ejection fraction, defined as an LVEF \ 55%. The control group used for comparison consisted of a previously published group of 27 healthy individuals, 56% male, with mean age of 16 years (range 8-20 years) [22] .
Results
Patient Characteristics
Myocardial ECV
Global myocardial ECV was 29 ± 6% in the DMD subjects and 24 ± 2% in the control group. The ECV in the DMD patients was significantly greater than the control subjects (p = 0.0001) ( Fig. 1 ). Twenty-two (47%) of DMD patients had global myocardial ECV values [28%; and 17 (36%) DMD patients had global myocardial ECV values [30%. Global myocardial ECV in LGE positive patients was 30 ± 7 and 27 ± 5% in the LGE-negative patients. There was no significant difference in global myocardial ECV between the LGE-positive and -negative patients (p = 0.0717). The ECV in DMD patients without evidence of LGE was significantly greater than control subjects (p = 0.0071). Global myocardial ECV in DMD patients with abnormally low LVEF was 32 ± 7 and 27 ± 5% in DMD patients with normal LVEF (p = 0.0064). Global myocardial ECV in DMD patients with normal LVEF was significantly elevated compared to control subjects (p = 0.0054).
LGE The presence of late gadolinium enhancement was found in 28 (60%) of the DMD subjects. Two DMD subjects that had no evidence of LGE had abnormally low LVEF. Eleven (39%) of the patients with positive LGE had normal LVEF. Using the previously defined four regions of interest, all LGE-positive patients demonstrated defects in the inferolateral segment. The next most commonly involved segment was the anterolateral segment (54%), followed by the inferior (39%) and septal (25%) segments. The mean myocardial ECV value for each segment is demonstrated in Fig. 2 . In each analyzed segment, ECV was significantly elevated in comparison with reported global ECV in the control population (p \ 0.05).
Relation Between ECV and LV Function
The relation of global myocardial ECV in DMD subjects and LV function was assessed by LVEF and indexed LV end diastolic volume. There was a significant inverse correlation between global ECV and LV ejection fraction (r = -0.46, p = 0.004) ( Fig. 3 ). There was a significant correlation between global ECV and indexed left ventricular end diastolic volume (r = 0.41, p = 0.004) ( Fig. 4) . Table 2 demonstrates, in the 47 DMD subjects, 12 different medication treatment groups, based on the medication regimen at the time of CMR. The most common treatment regimen included a combination of steroid and angiotensinconverting-enzyme inhibitor in 11 (23%) subjects. Treatment with steroid alone occurred in 10 (21%) of subjects. Two (4%) subjects were on no medications. A Kruskal-Wallis H test showed that there was no statistically significant difference in ECV between the different medication groups, v 2 (11) = 18.1, p = 0.08. Fig. 1 Global ECV in controls versus DMD. Comparison between global myocardial extracellular volume fraction (ECV) between control population [22] and duchenne muscular dystrophy (DMD) patients 
Relation Between ECV and Medication
Relation Between ECV and Age
There was no significant correlation between global ECV and age (r = 0.07, p = 0.065) ( Fig. 5 ).
Observer Variability
Five patients (10%) were randomly selected and analyzed for ECV for inter-and intra-observer variability. Interobserver mean differences for ECV were 0.3% (95% confidence interval 1.9 to -1.3%). Intra-observer mean differences for ECV were 0.2% (95% confidence interval 1.3 to -0.9%).
Discussion
With this study, we demonstrated that global ECV is significantly higher in DMD patients in comparison to published controls. Furthermore, we demonstrated that CMR ECV quantification by T1 mapping method is a feasible, non-invasive method to monitor cardiac involvement in a pediatric DMD population. ECV measurements correlated well with other metrics of cardiovascular function including left ventricular ejection fraction and indexed left ventricular end diastolic volume.
To our knowledge, this is the largest such description of ECV in pediatric DMD patients. BB beta blocker, ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, ECV extracellular volume fraction The degree of cardiac involvement in DMD patients can be difficult to establish. Body habitus may limit the fidelity of more traditionally used trans-transthoracic imaging for accurate evaluation of left ventricular systolic function. With early loss of ambulation reliance on standard questions for assessment of heart failure symptoms, such as ability to keep up with peers, is challenging if not impossible. Comorbid scoliosis, limited patient positioning, and body habitus challenges even the most astute clinician's physician examination skills. There is need for additional tools to help assess and monitor cardiac involvement in this group of muscular dystrophy patients.
Myocardial loss with fibrofatty replacement is the principle histologic feature in DMD [11, 12] . Previous studies have demonstrated that development and detection of LGE in DMD patients are strong markers of LV systolic dysfunction and myocardial fibrosis burden by LGE imaging correlates with LV systolic dysfunction [16] .
LGE imaging is a useful marker to follow when it develops; however, low levels of diffuse fibrosis likely precede development of conspicuous LGE, and greater sensitivity to diffuse myocardial fibrosis may help to detect cardiac involvement and direct therapeutics earlier.
Detection of cardiac involvement by ECV and correlation with LVEF has been demonstrated in Becker Muscular Dystrophy [13] . Investigators were additionally able to demonstrate that important fibrosis was detectable with ECV even in areas of LGE-negative, normal appearing myocardium. In the DMD population, myocardial T1-LL (Look-Locker) imaging, as a measure of myocardial fibrosis, also demonstrated abnormally shortened values as compared to controls. Those investigators similarly demonstrated shortened myocardial T1-LL in areas of normal LGE-negative myocardium [21] .
Our data, in the largest group of DMD patients reported with ECV determination, demonstrated that ECV detected cardiac involvement in patients elevated compared to a published control population. In our patients, although there was a trend toward significance, we were unable to demonstrate a significant difference in global myocardial ECV in patient with and without evidence of LGE. This finding reflects the diffuse, rather than focal, nature of the fibrotic process occurring in the myocardium in DMD. Due to the heterogeneity of the disease, recognition of cardiac involvement with LGE imaging may not always be a reliable marker for cardiac involvement in DMD patients. Previous studies have demonstrated a continuous relationship between age and ECV, with ECV increasing with age [25] . In our population, there was no correlation between age at time of CMR and ECV. This may be explained by our limited age range of pediatric DMD population.
Our data do suggest that there is evidence of myocardial involvement in the absence of other, previously used markers of myocardial function and fibrosis. In comparison to published normal controls, our patients demonstrated abnormally elevated global myocardial ECV values in the absence of evidence of LGE and in the face of normal left ventricular ejection fraction. With additional regional analysis, all regions, even those with the lowest frequency of LGE, demonstrated abnormally elevated myocardial ECV. These findings give further credence to the notion that global myocardial ECV measurement is an additional parameter that can be used to identify early myocardial involvement.
Measuring strain data as a marker of myocardial dysfunction in our patients was not performed for this project. It is planned as the next stage of the project.
Limitations
Our study had a number of limitations. Our CMR, demographic, and clinical data were collected retrospectively; therefore, results must be interpreted with the inherent limitations of retrospective analysis. As in any T1 imaging technique, the variability of age and heart rates can influence the generalizability of our results. Larger sample size and inclusion of larger age range of patients could potentially alter our observed correlations. The majority of our patients were taking cardiovascular medications, often with the goal to minimize the development of myocardial fibrosis. The influence of these medications may confound the evaluation of LGE, ejection fraction, and ECV and further studies to evaluate their influence in this disease process are required. A control population of children in CMR imaging is ethically and practically difficult to create. The requirement of ECV imaging on the administration of gadolinium-based contrast agents precludes its use for research only studies. Our study required comparison to previously published normal which are limited in a pediatric population. Future establishment of normal range of values should minimize such limitations. The control population used for comparison was composed of 56% male subjects [22] . In comparison, our population was composed entirely of male subjects. This difference in gender distribution may influence our results; however, studies have demonstrated that comparison of native T1, k, and ECV by gender has not demonstrated any significant difference [17] in a healthy population of patients. Therefore, any influence gender may have had on our results is likely to be minimal.
Conclusions
Global myocardial ECV is significantly higher in the DMD population when compared to control. Detection of abnormal myocardial ECV is a strong marker for fibrosis and cardiac involvement in DMD population. Future studies to evaluate the clinical utility of ECV to direct and monitoring management in the treatment and prevention of cardiac involvement in DMD patients are warranted.
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